Bangmao Wang

机构：Nankai University, Tianjin Medical University General Hospital · ORCID：0000-0002-4702-9711

发表论文 267 篇 · 总被引 6102 次 · h-index 41

代表论文

• Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study (2024 · The Lancet · 被引 107)
• Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies (2024 · The Lancet · 被引 95)
• Desulfovibrio vulgaris flagellin exacerbates colorectal cancer through activating LRRC19/TRAF6/TAK1 pathway (2024 · Gut Microbes · 被引 23)
• A Saccharomyces boulardii-derived antioxidant protein, thioredoxin, ameliorates intestinal inflammation through transactivating epidermal growth factor receptor (2024 · Pharmacological Research · 被引 17)
• Blocking Fusobacterium nucleatum-host cell interactions with responsive supramolecular GalNAc-derived nanoplatform for enhanced chemotherapy in colorectal cancer (2024 · Nano Today · 被引 16)
• Machine learning-based characterization of PANoptosis-related biomarkers and immune infiltration in ulcerative colitis: A comprehensive bioinformatics analysis and experimental validation (2025 · International Immunopharmacology · 被引 13)